VenaSeal Sapheon Closure System Pivotal Study (VeClose)

Inclusion Criteria: 1. Age ≥ 21 years and ≤ 70 years of age at the time of screening 2. Reflux in the great saphenous vein (GSV) greater than 0.5 sec reflux 3. One or more of the following symptoms related to the target vein: aching, throbbing, heaviness, fatigue, pruritis, night cramps, restlessness, generalized pain or discomfort, swelling 4. GSV diameter while standing of 3-12 mm throughout the target vein as measured by Duplex ultrasound 5. Clinical, etiology, assessment and pathophysiology (CEAP) classification of C2 (if symptomatic) - C4b 6. Ability to walk unassisted 7. Ability to attend follow-up visits 8. Ability to understand the requirements of the study and to provide informed consent Exclusion Criteria: 1. Life expectancy \< 1 year 2. Active treatment for malignancy other than non-melanoma skin cancer 3. Symptomatic peripheral arterial disease with ankle-brachial index (ABI) \<0.89 4. Daily use of narcotic or non-steroidal anti-inflammatory pain medications to control pain associated with GSV reflux 5. Current, regular use of systemic anticoagulation (e.g., warfarin, heparin) 6. Previous or suspected deep vein thrombosis (DVT) or pulmonary embolus (PE) 7. Previous superficial thrombophlebitis in GSV 8. Previous treatment of venous disease in target limb, other than spider vein treatment 9. Known hypercoagulable disorder 10. Conditions which prevent vein treatment with either RFA or VenaSeal SCS 11. Immobilization or inability to ambulate 12. Pregnant prior to enrollment 13. Tortuous GSV, which, in the opinion of the investigator, will limit catheter placement or require more than one primary access site 14. Aneurysm of the target vein with local diameter \>12 mm 15. Significant, incompetent, ipsilateral small saphenous, intersaphenous or anterior accessory great saphenous vein(s) 16. Known sensitivity to cyanoacrylate (CA) adhesives 17. Current participation in another clinical study involving an investigational agent or treatment, or within the 30 days prior to enrollment 18. Patients who require bilateral treatment during the next 3 months 19. Patients who require additional ipsilateral treatments on the same leg within 3 months following treatment